MTOR and Dravet syndrome: The favorable outcomes of rapamycin treatment seem to rely on its ability to rescue molecular pathways associated with aberrant mTOR phosphorylation, whose alteration accelerate the age-related neurodegenerative process and increase the risk of AD development in DS.